Ergomed plc Director dealings (0540J)

TIDMERGO

RNS Number : 0540J

Ergomed plc

18 August 2021

Director Dealings

Guildford, UK - 18 August 2021 : Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that on 17 August 2021, in order to meet demand from new and existing investors, Dr Miroslav Reljanović, Executive Chairman of Ergomed, and Richard Barfield, Chief Financial Officer of Ergomed, sold 1,200,000 ordinary shares of 1p each in the Company ("Ordinary Shares") and 50,000 Ordinary Shares respectively at a price of 1200 pence per share.

Following these sales, Dr Miroslav Reljanović holds 9,679,297 Ordinary Shares representing 19.8% of the Company's issued share capital and Richard Barfield holds 50,000 Ordinary Shares representing 0.1% of the Company's issued share capital.

The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.

 
 1     Details of the person discharging managerial responsibilities/person 
        closely associated 
 a)    Name                                     Dr Miroslav Reljanović 
      ---------------------------------------  ----------------------------------- 
 2     Reason for the notification 
      ---------------------------------------------------------------------------- 
 a)    Position/status                          Executive Chairman 
      ---------------------------------------  ----------------------------------- 
 b)    Initial notification                     Initial Notification 
        /Amendment 
      ---------------------------------------  ----------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ---------------------------------------------------------------------------- 
 a)    Name                                     Ergomed plc 
      ---------------------------------------  ----------------------------------- 
 b)    Legal Entity                             213800BVS8I9VMC1AP84 
        Identifier 
      ---------------------------------------  ----------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ---------------------------------------------------------------------------- 
 a)    Description                              Ordinary shares of 1 pence each 
        of the financial 
        instrument, 
        type of instrument                       GB00BN7ZCY67 
 
        Identification 
        code 
      ---------------------------------------  ----------------------------------- 
 b)    Nature of the                            Sale of Shares 
        transaction 
      ---------------------------------------  ----------------------------------- 
 c)    Currency                                 GBP 
      ---------------------------------------  ----------------------------------- 
 d)    Price(s) and                                 Price(s)          Volume(s) 
        volume(s) 
      ---------------------------------------  -----------------  ---------------- 
                             GBP12.00                                 1,200,000 
  --------------------------------------------------------------  ---------------- 
 
 e)    Aggregated information 
 
        - Aggregated 
        volume                                    1,200,000 
 
        - Price                                   GBP12.00 
 
        - Aggregated                              GBP14,400,000 
        total 
      ---------------------------------------  ----------------------------------- 
 f)    Date of the                              17 August 2021 
        transaction 
      ---------------------------------------  ----------------------------------- 
 g)    Place of the                             London Stock Exchange, AIM 
        transaction 
      ---------------------------------------  ----------------------------------- 
 
 
 1     Details of the person discharging managerial responsibilities/person 
        closely associated 
 a)    Name                                     Richard Barfield 
      ---------------------------------------  ----------------------------------- 
 2     Reason for the notification 
      ---------------------------------------------------------------------------- 
 a)    Position/status                          Chief Financial Officer 
      ---------------------------------------  ----------------------------------- 
 b)    Initial notification                     Initial Notification 
        /Amendment 
      ---------------------------------------  ----------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ---------------------------------------------------------------------------- 
 a)    Name                                     Ergomed plc 
      ---------------------------------------  ----------------------------------- 
 b)    Legal Entity                             213800BVS8I9VMC1AP84 
        Identifier 
      ---------------------------------------  ----------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ---------------------------------------------------------------------------- 
 a)    Description                              Ordinary shares of 1 pence each 
        of the financial 
        instrument, 
        type of instrument                       GB00BN7ZCY67 
 
        Identification 
        code 
      ---------------------------------------  ----------------------------------- 
 b)    Nature of the                            Sale of Shares 
        transaction 
      ---------------------------------------  ----------------------------------- 
 c)    Currency                                 GBP 
      ---------------------------------------  ----------------------------------- 
 d)    Price(s) and                                 Price(s)          Volume(s) 
        volume(s) 
      ---------------------------------------  -----------------  ---------------- 
                             GBP12.00                                  50,000 
  --------------------------------------------------------------  ---------------- 
 
 e)    Aggregated information 
 
        - Aggregated 
        volume                                    50,000 
 
        - Price                                   GBP12.00 
 
        - Aggregated                              GBP600,000 
        total 
      ---------------------------------------  ----------------------------------- 
 f)    Date of the                              17 August 2021 
        transaction 
      ---------------------------------------  ----------------------------------- 
 g)    Place of the                             London Stock Exchange, AIM 
        transaction 
      ---------------------------------------  ----------------------------------- 
 

ENDS

Enquiries :

Ergomed plc Tel: [phone]

Miroslav Reljanović (Executive Chairman)

Richard Barfield (Chief Financial Officer)

Numis Securities Limited Tel: [phone]

Freddie Barnfield / Matthew O'Dowd (Nominated Adviser)

James Black (Broker)

Peel Hunt LLP Tel: [phone]

James Steel / Dr. Christopher Golden

   Consilium Strategic Communications                                       Tel: [phone] 

Chris Gardner / Matthew Neal [e-mail]

Angela Gray

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit: http://ergomedplc.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHGPUQURUPGGGR

(END) Dow Jones Newswires

August 18, 2021 07:09 ET (11:09 GMT)